Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.45
+0.08 (0.96%)
At close: May 22, 2026, 4:00 PM EDT
8.38
-0.07 (-0.83%)
After-hours: May 22, 2026, 7:59 PM EDT
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
900
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$752,000
Profits / Employee
-$9,556
Market Cap
435.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 900 | 0 | - |
| Dec 31, 2024 | 900 | -700 | -43.75% |
| Dec 31, 2023 | 1,600 | -900 | -36.00% |
| Dec 31, 2022 | 2,500 | 84 | 3.48% |
| Dec 31, 2021 | 2,416 | 216 | 9.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 960 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Evolus | 350 |
| Esperion Therapeutics | 294 |
| Akebia Therapeutics | 194 |
| Aquestive Therapeutics | 147 |
EBS News
- 5 days ago - Emergent BioSolutions to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine - TheFly
- 7 days ago - Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - GlobeNewsWire
- 14 days ago - Hantavirus cases spark surge in pharma and biotech stocks — here's why - CNBC
- 25 days ago - Emergent BioSolutions Earnings Call Transcript: Q1 2026 - Transcripts
- 25 days ago - Emergent BioSolutions Earnings release: Q1 2026 - Filings
- 25 days ago - Emergent BioSolutions Slides: Q1 2026 - Filings
- 25 days ago - Emergent BioSolutions Quarterly report: Q1 2026 - Filings